镰状细胞病患者初次全膝关节置换术后10年累积翻修发生率及翻修指征
基于大型全国数据库,将1010例镰状细胞病(SCD)患者按年龄、性别和合并症指数1:4匹配至4020例对照,比较初次全膝关节置换术后10年累积翻修发生率及翻修指征。SCD患者10年全因翻修风险高于未匹配对照(HR 1.86,P<.001)和匹配对照(HR 1.39,P=.034),且因假体周围感染、无菌性松动和血肿行翻修的比例均更高。作者认为应加强SCD患者围手术期和术后外科优化。
要点
- SCD患者10年全因翻修风险高于未匹配对照(HR 1.86,P<.001)。
- 匹配合并症后SCD患者10年全因翻修风险仍更高(HR 1.39,P=.034)。
- SCD患者因假体周围感染、无菌性松动和血肿行翻修的比例均更高。
核心结论
- 独立于其他合并症,SCD患者因假体周围感染、无菌性松动和血肿行翻修的可能性高于无SCD患者。
- 由于这些并发症风险高,作者建议对SCD患者实施围手术期和术后外科优化。
研究设计与样本
- 利用大型全国数据库识别接受初次全膝关节置换术的患者。
- 将SCD患者按年龄、性别和合并症指数以1:4比例匹配至对照队列。
- 共识别1010例SCD患者,未匹配对照纳入100000例,匹配对照纳入4020例。
主要发现
- 与未匹配对照相比,SCD患者10年全因翻修风险更高(HR 1.86;P<.001),因假体周围感染(P<.001)、无菌性松动(P<.001)和血肿(P<.001)行翻修的比例更高。
- 与匹配对照相比,SCD患者10年全因翻修风险更高(HR 1.39;P=.034),因假体周围感染(P=.044)、无菌性松动(P=.003)和血肿(P=.019)行翻修的比例更高。
临床怎么用
- 作者建议对SCD患者实施围手术期和术后外科优化,以应对假体周围感染、无菌性松动和血肿的高风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Literature regarding total knee arthroplasty (TKA) outcomes in sickle cell disease (SCD) is limited. Moreover, 10-year survivorship of SCD implants is unknown. This study aimed to observe 10-year cumulative incidence and indications for revision TKA in patients who did and did not have SCD. METHODS: Patients who underwent primary TKA were identified using a large national database. The SCD patients were matched by age, sex, and a comorbidity index to a control cohort in a 1:4 ratio. The 10-year cumulative incidence rates were determined using Kaplan-Meier survival analyses. Multivariable analyses were conducted using Cox proportional hazard modeling. Chi-squared analyses were conducted to compare indications for revision between cohorts. In total, 1,010 SCD patients were identified, 100,000 patients included in the unmatched control, and 4,020 patients included in the matched control. RESULTS: Compared to the unmatched control cohort, SCD patients exhibited higher 10-year all-cause revision (HR: 1.86; P < .001) with higher proportions of revisions for periprosthetic joint infection (PJI) (P < .001), aseptic loosening (P < .001), and hematoma (P < .001). Compared to the matched control, SCD patients had higher 10-year all-cause revision (Hazard Ratio (HR): 1.39; P = .034) with a higher proportion of revisions for PJI (P = .044), aseptic loosening (P = .003), and hematoma (P = .019). CONCLUSION: Independent of other comorbidities, SCD patients are more likely to undergo revisions for PJI, aseptic loosening, and hematoma compared to patients who do not have SCD. Due to the high-risk of these complications, perioperative and postoperative surgical optimization should be enforced in SCD patients.
引用
- Parel PM, Kuyl EV, Agarwal AR, et al. 10-Year Cumulative Incidence and Indications for Revision Total Knee Arthroplasty Among Patients Who Have Sickle Cell Disease. J Arthroplasty. 2023. PMID: 37003459. doi:10.1016/j.arth.2023.03.070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。